Show simple item record

dc.contributor.advisorOffner, Gwynnethen_US
dc.contributor.authorCespedes-Gomez, Omaren_US
dc.date.accessioned2019-08-14T19:18:04Z
dc.date.available2019-08-14T19:18:04Z
dc.date.issued2019
dc.identifier.urihttps://hdl.handle.net/2144/37099
dc.description.abstractIn 2016, there were 250,000 new cases of invasive cancer and 60,000 of ductal carcinoma in situ. Mammograms are used to screen for cases of disease, but the literature shows that mammograms are highly dependent on patient characteristics and do not majorly impact mortality rates from invasive cancer. Additionally, they are prone to false-positives, false-negatives, and overdiagnosis in cases of in situ cancer, with overdiagnosis exposing patients to the side effects of treatment. Better screening tests are needed, and a potential solution can be to extend molecular screening methods often used in advanced stage 1 and higher cancers to stage 0 ductal carcinoma in situ cases. This new test would prevent overdiagnosis, be more accurate, and prevent unnecessary screening as well as be in line with the future of cancer care in the US.en_US
dc.language.isoen_US
dc.subjectMedicineen_US
dc.subjectBreast canceren_US
dc.subjectMammogramsen_US
dc.titleA novel therapy for breast cancer: implications for treatment accessen_US
dc.typeThesis/Dissertationen_US
dc.date.updated2019-08-09T16:03:38Z
etd.degree.nameMaster of Scienceen_US
etd.degree.levelmastersen_US
etd.degree.disciplineMedical Sciencesen_US
etd.degree.grantorBoston Universityen_US


This item appears in the following Collection(s)

Show simple item record